1	Title	
2	Rapid en	nergence and transmission of virulence-associated mutations in the oral poliovirus
3	vaccine following vaccination campaigns	
4	Katharin	e S. Walter ¹ *, Jonathan Altamirano ² , ChunHong Huang ³ , Yuan J. Carrington ³ , Frank
5	Zhou ³ , Jason R. Andrews ⁴ , Yvonne Maldonado ^{3,4}	
6	1.	Division of Epidemiology, University of Utah, Salt Lake City, UT 84105, USA
7	2.	Department of Epidemiology and Population Health, Stanford University School of
8		Medicine, Stanford, CA 94305, USA
9	3.	Department of Pediatrics, Stanford University School of Medicine, Stanford, CA,
10		USA
11	4.	Division of Infectious Diseases and Geographic Medicine, Stanford University
12		School of Medicine, Stanford, CA 94305, USA
13	*Corresponding Author	
14	Email:	Katharine.Walter@hsc.utah.edu
15	Author	Contributions: YM, JRA, and KSW designed the study. JA, CH, YC, and FZ
16	conducte	ed DNA extractions, sample preparation, Sanger sequencing, and data management. KW
17	performed data analysis and drafted the paper. YM and JRA reviewed the paper and supervised	
18	the project.	
19	Compet	ing Interest Statement: All authors declare no competing interests.
20	Classific	eation: epidemiology, poliovirus
21	Keywor	ds: poliovirus, vaccines, virus evolution, transmission, environmental surveillance
22		
23		

- 24 Abstract
- 25

26 There is an increasing burden of circulating vaccine-derived polioviruses (cVDPVs) due 27 to the continued use of oral poliovirus vaccine (OPV). However, the informativeness of routine 28 OPV VP1 sequencing for the early identification of viruses carrying virulence-associated 29 reversion mutations has not been directly evaluated in a controlled setting. We prospectively 30 collected 15,331 stool samples to track OPV shedding from vaccinated children and their 31 contacts for ten weeks following an immunization campaign in Veracruz State, Mexico and 32 sequenced VP1 genes from 358 samples. We found that OPV was genetically unstable and 33 evolves at an approximately clocklike rate that varies across serotypes and by vaccination status. 34 Alarmingly, 28% (13/47) of OPV-1, 12% (14/117) OPV-2, and 91% (157/173) OPV-3 of Sabin-35 like viruses had ≥ 1 known reversion mutation. Our results suggest that current definitions of 36 cVDPVs may exclude circulating virulent viruses that pose a public health risk and underscore 37 the need for intensive surveillance following OPV use.

38

39 Introduction

The global use of oral poliovirus vaccine (OPV), a live, attenuated virus, has been essential in reducing the burden of poliomyelitis caused by wild poliovirus by 99.9% since 1988^{1,2}. The vaccine covers all three wild poliovirus serotypes, is inexpensive, easy to deliver, and—because it is a live virus—is transmissible from vaccinated children onwards, extending the reach of vaccination campaigns. However, OPV vaccination is risky—the vaccine virus is genetically unstable and continues to evolve in vaccinated individuals and their contacts. If OPV mutates at positions responsible for attenuation of the vaccine virus, it can regain virulence. OPV

47	can regain virulence within a vaccinated individual, causing vaccine-associated paralytic
48	poliomyelitis, though rarely ³ . OPV may also revert to virulence over transmission chains,
49	generating outbreaks of circulating vaccine derived polioviruses (cVDPVs).
50	To reduce the risks of cVDPVs, in May 2016, trivalent OPV vaccines (containing
51	serotypes 1, 2, and 3) were replaced with a bivalent OPV (containing serotypes 1 and 3),
52	following World Health Organization recommendations. The WHO recommended that routine
53	immunization with at least one dose of inactivated poliovirus vaccine (IPV) prior to the switch to
54	bivalent OPV, to increase protection against paralytic disease ⁴ . However, access to IPV was
55	limited, leaving large populations of children immunologically naïve to poliovirus type 2. Since
56	the global switch to bivalent OPV, the majority of paralytic poliovirus cases are now caused by
57	cVDPVs, not wild poliovirus, the majority of which are serotype 2 viruses (cVDPV2). From
58	2016 to 2022, type 2 cVDPVs emerged 68 times in 34 countries, leading to more than 1500 cases
59	of paralytic polio ⁵ (Fig. 1).
60	The current public health response to outbreaks of cVDPV type 2 is vaccination with
61	monovalent OPV-2 (mOPV-2), to increase population-level immunity and reduce transmission
62	risk. However, the outbreak response itself is risky, as mOPV-2 use can generate new cVDPV
63	outbreaks.
64	Outbreak responses are guided by routine testing of cases of acute flaccid paralysis in
65	

children less 15 and environmental surveillance in more than 30 high-risk countries and
sequencing of the poliovirus VP1 gene⁶. The Global Polio Eradication Initiative (GPEI) defines
VDPVs by their divergence from OPV in the VP1 gene⁶. cVDPVs are defined by evidence of
VDPV transmission, through genetically linked viruses from individuals with acute flaccid
paralysis or environmental samples⁶ and assigned to new or existing genetic clusters^{7,8}. The

identification of new cVPDVs results in an epidemiological investigation and an immunization
 response⁶.

72 Previous genomic studies of type 2 cVDPVs and OPV-2 shedding in vaccinated children 73 and contacts have identified strong within-host selection and tight transmission bottlenecks that 74 govern the early evolution of type 2 viruses away from the Sabin vaccine strain along a predictable pathway to virulence^{11,12}. Yet previous studies have not yet integrated detailed 75 76 molecular and epidemiological data to assess the use of VP1 sequencing for the early 77 identification of viruses posing a public health risk. Given that global surveillance and outbreak 78 responses rely on VP1 sequencing, we need a better understanding of how informative VP1 79 diversity is for characterizing risk of reversion to virulence and transmission of virulent viruses. 80 Here, we followed the evolution and transmission of the three OPV serotypes during a 81 prospective study of OPV shedding following a vaccine campaign in semi-rural communities in Veracruz State, Mexico¹³. We sequenced OPV VP1 genes from stool sampled from vaccinated 82 83 children, their household contacts, and community members in unvaccinated households for 10 84 weeks following the vaccination campaign. This provides a rare opportunity to observe the early 85 evolution and transmission of the three OPV serotypes following vaccination campaigns and to evaluate the current use of VP1 sequencing as an epidemiological tool. 86

87

88 Methods

89

90 *Prospective sampling*

91 We conducted a prospective study of OPV shedding and transmission following a
92 trivalent OPV vaccination campaign during Mexico's February 2015 National Health Week in

three semi-rural populations in Orizaba, Veracruz State¹³ (Fig. 2). Wild poliovirus has not been reported since 1994 in Mexico. Mexico's national vaccine program has included routine IPV as well as two annual OPV vaccination campaigns since 2007 and therefore provides a model for transmission of OPV in a setting with routine IPV immunization, an epidemiological context which will increasingly exist as IPV replaces OPV and OPV is only used as a tool for cVDPV or wild poliovirus outbreak response.

99 We randomized 466 households to the vaccine and no-vaccine arm of our study across 100 three communities which were assigned to OPV vaccination rates of 10%, 30%, and 70%. In 101 total, 155 children (8.5% of the population) were vaccinated with trivalent OPV during the 102 National Health Week. Vaccinated children and their household contacts were followed 103 prospectively and stool was collected from all members of sampled households 1 day prior to 104 the National Health Week OPV immunization campaign, and 1, 4, 7, 10, 14, 21, 28, 51, and 71 days following, for a total of 10 samples per person¹³. Study nurses collected immunization 105 106 histories and additional demographic and clinical metadata from all study participants. 107 The study was approved by the Stanford University Institutional Review Board (Protocol 108 #31546), the Comité de Etica, Bioseguridad e Investigación of the Instituto Nacional de Salud 109 Pública (CI: 1260, No. 1581), and the Instituto Veracruzano para la Formación e Investigación 110 en Salud (SESVER/IVEFIS//SIS/DIB/0109/02014, classification 15S).

111

112 Sanger sequencing of VP1 gene

We extracted RNA from frozen stool samples and tested samples for OPV with serotypespecific RT-qPCR^{13,14}. We Sanger sequenced the VP1 gene using the Y7 and Q8R primers¹⁵ and

generated consensus sequences by aligning forward and reverse sequences to serotype-specificreference genomes in *Geneious* v7.

117

118	Bioinformatic analysis
119	We aligned VP1 gene sequences of each OPV serotype to the corresponding Sabin
120	vaccine sequence (GenBank Accession Numbers: AY184219, AY184220, AY184221) with
121	MAFFT v.7 ¹⁶ , with the algorithm recommended for closely related viral sequences
122	(https://mafft.cbrc.jp/alignment/software/closelyrelatedviralgenomes.html), preserving the
123	alignment length of the reference sequence. We used the default alignment strategy and a
124	nucleotide sequence scoring matrix of 1PAM / κ =2, recommended for closely related DNA
125	sequences.
126	We quantified pairwise distances between samples with the R package ape (pairwise
127	deletion = $TRUE$) ¹⁷ . For household contacts and community members who were not vaccinated
128	with OPV, we measured time since vaccination as the time since vaccination of the household
129	member or the earliest vaccination given in the community, respectively. We visualized
130	haplotype networks built from minimum spanning trees with the R package <i>pegas</i> ¹⁸ .
131	
132	Data availability.
133	The full-length VP1 sequences used in our study are publicly available on GenBank
134	(Submission 2683280, 2683353, and 2683683). The references sequences used for sequence
135	alignment are publicly available on GenBank AY184219, AY184220, AY184221). Multiple

136 sequence alignments and metadata to reproduce figures and analyses are publicly available on

137 GitHub (https://github.com/ksw9/opv-consensus).

138 139 140 *Code availability.* 141 Code for analysis and figures is publicly available on GitHub 142 (https://github.com/ksw9/opv-consensus). 143 144 Global poliovirus data. 145 We accessed World Health Organization poliovirus case data from the WHO extranet 146 (https://extranet.who.int/polis/public/CaseCount.aspx), including both global and country-level 147 reported cases from 2000-2022. 148 149 **Results** 150 151 **Sample collection** During a prospective study of OPV shedding following a National Health Week 152 153 vaccination campaign in Veracruz State, Mexico, we collected 15,331 stool samples over 10 154 weeks following vaccination. From these samples, 551 samples were positive for at least one 155 OPV serotype, including 267 OPV-1, 402 OPV-2, and 317 OPV-3 positive samples. We 156 sequenced 358 high quality VP1 genes from 174 individuals, including 18.4% (49/267) positive 157 OPV-1 samples, 33.8% (136/402) positive OPV-2 samples, and 54.5% (173/317) OPV-3 158 samples. Sequence data was available for 99 vaccinated children, 41 household contacts of 159 vaccinated children, 31 members of the community outside of vaccinated households, and 3 individuals without known vaccination status. For 84 infections (unique individuals and 160

serotypes), longitudinal samples were available at 2-5 sampling points. The prospective study
was conducted in three semi-rural villages; samples include 106 individuals from Capoluca,
where 70% of children less than five in participating households were vaccinated; 49 from
Campo Grande, where 30% were vaccinated; and 19 individuals from Tuxpanguillo, where 10%
were vaccinated.

166

167 Genetic instability of OPV

We observed a rapid rise of VP1 diversity in all three serotypes over weeks following OPV vaccination. The most common haplotype for both OPV-1 and OPV-2 in each sampling location represents the Sabin vaccine strain (Fig. 3), with a star-like pattern in the haplotype networks, where most haplotypes are directly connected to the Sabin haplotype. Outside of the dominant haplotype, most haplotypes are represented by a single sample.

173 In contrast, for OPV-3, the dominant haplotype differs by a single nucleotide

174 polymorphism (SNP) from the vaccine strain, a previously described attenuating site, C2493U

175 (Fig. 3). Again, there is a star-like pattern of OPV-3 diversity, with many branches stemming

176 directly from the dominant haplotype. As with OPV-2 and OPV-3, most haplotypes outside the

177 dominant haplotype are represented by a single sample.

178

179 Clock-like early evolution of OPV following vaccination campaigns

The Global Polio Eradication Initiative (GPEI) defines VDPVs by their divergence from the Sabin vaccine in the VP1 gene (>1% divergent or \geq 10 substitutions for serotypes 1 and 3, 0.6% divergent of \geq 6 substitutions for serotype 2)⁶. The majority, 99% (337/340), of all samples sequenced following vaccination fell under the thresholds for a VDPV. However, two samples from vaccinated children, collected 4 days after vaccination met the definition of a VDPV2 (VP1
genetic distance 14 and 8 SNPs from Sabin 2) and one sample from a household contact sampled
30 days following vaccination met the definition of a VDPV1 (10 SNPs distant from Sabin 1)
(Fig. 4).

188 We then examined if the early evolution of OPV follows a molecular clock and, therefore, if 189 OPV divergence from Sabin vaccine strains could be used to estimate the duration of viral 190 circulation. Genetic divergence of OPV-1 was significantly associated with time following 191 vaccination in both vaccinated children (p < 0.001, Pearson's r = 0.42) and non-vaccinated 192 individuals (p < 0.001, Pearson's r = 0.90) (Fig. 4). When considering all samples together, the observed mutations in OPV-1 corresponded to a VP1 gene evolutionary rate of 1.2×10^{-4} 193 194 substitutions per site per day. Genetic divergence of OPV-2 was not significantly associated with 195 time following vaccination in vaccinated children (p=0.3, Pearson's r = -0.11) and was positively 196 correlated with time among non-vaccinated individuals, though not significantly so (p =0.07, 197 Pearson's r = 0.31) (Fig. 4). OPV-3 divergence was positively associated with time following 198 vaccination for non-vaccinated individuals (p = 0.007, Pearson's r = 0.48), but not vaccinated 199 children (p = 0.26, Pearson's r = -0.1)

We reasoned that mutations at known attenuating positions may be under strong selection and could affect an estimate of molecular clock. However, excluding the known attenuating sites in the VP1 gene did not substantially change observed associations between genetic divergence and time (Fig. S1).

204

205 Moderate signal of recent transmission in OPV VP1 gene sequence diversity

VP1 genetic diversity is also used by the GPEI to determine if a VDPV is genetically
linked to previously collected environmental or clinical samples, which makes it a cVDPV, and
whether viruses are linked to a previously identified cVDPV emergence or constitute a new
emergence.

210 To test whether VP1 sequence divergence is genetically structured and could provide211 evidence of

212 recent transmission, as is done with several pathogens, we compared pairwise genetic distances

213 across samples. As expected with the relatively short duration of sampling following vaccination

214 campaigns, 28.9% (694/2400) of OPV-1; 40.6% (67,16/16,504) of OPV-2; and 42.0%

215 (12,498/29,974) of OPV-3 VP1 pairs of sequences were identical. Mean pairwise distance was

216 2.4 SNPs for OPV-1, 1.5 SNPs for OPV-2, and 1.4 SNPs for OPV-3 (Fig. 5).

In a general linear model, pairwise genetic distance between VP1 samples was elevated for individuals from the same household (aOR: 1.29; 95% CI: 1.11-1.50), from the same community (aOR: 1.49; 95% CI: 1.34-1.64), and from different communities (aOR: 1.63; 95% CI: 1.48-1.80), compared to samples collected from an individual. As expected, longitudinal samples from an individual were mostly conserved over the sampling time. Genetic structure varied across serotypes: compared to OPV-1, we observed decreased pairwise genetic distances for both OPV-2 (aOR: 0.64; 95% CI: 0.62-0.65) and OPV-3 (aOR: 0.58; 95% CI: 0.57-0.60).

224

225 Rapid loss of OPV attenuating mutations in the VP1 gene following vaccination campaigns

We then examined known mutations at key attenuating sites in the vaccine virus,

associated with the reversion of vaccine viruses to virulence. Of three known virulence

attenuating substitutions in the OPV-1 VP1 gene, 16% (8/49) of samples had a A2749G (Sabin

to virulent wildtype) mutation, including 4 vaccinated children and 2 household contacts. The
mutation first appeared 14 days following vaccination in a vaccinated child and contact in one
house and in another vaccinated child independently and rose in frequency, although there were
limited OPV-1 samples available 4+ weeks after vaccination. It was observed in stool up to 52
days after the vaccination campaign. A single sample shed by a vaccinated child harbored a
A2795G substitution, and no U2879C attenuating mutations occurred (Fig. 6).

235 Among OPV-2 samples, the known VP1 reversion mutation, U2909C/A, occurred in 236 4.4% (6/136) of samples, in four vaccinated children. The substitution was first observed 7 to 14 237 days after vaccination; two children shed OPV-2 carrying this reversion mutation on multiple 238 days. The mutation was observed in stool up to 21 days following the vaccination campaign, 239 though again, there were limited OPV-2 samples available 4+ weeks after vaccination. No individuals had mutations present at the adjacent site 2908, also associated with reversion¹⁹. 240 241 Among OPV-3 samples, the majority, 91% (157/173), had a C2493A/G/U eversion 242 substitution and an additional 11 samples had a mixed allele or no allele call at that site, possibly 243 evidence of mixed infection. Samples with a C2493A/G/U mutation included 95% (89 of 94) of 244 individuals with OPV-3 sequences available, including 63 vaccinated children, 18 household 245 members, and 8 individuals outside of vaccinated households. The mutation first appeared one 246 day following the vaccination in vaccinated children, household members, and individuals 247 outside vaccinated households and it was observed in stool up to 72 days after the vaccination 248 campaign from a vaccinated child and 70 and 54 days from virus shed in a household member 249 and community member, respectively.

250

251 **Discussion**

Global poliovirus surveillance uses molecular epidemiology to directly guide outbreak responses. However, the informativeness of the routinely sequenced marker gene, VP1, in the early identification of VDPVs posing a public health risk has not been evaluated in a controlled setting.

256 Here, we leveraged OPV sampled for 10 weeks following an immunization campaign in a 257 population previously vaccinated with IPV to assess the epidemiological information within VP1 258 samples. We found that all three OPV serotypes are genetically unstable in the weeks following 259 vaccination campaigns, consistent with previous reports. We identified evidence of clocklike 260 VP1 evolution across serotypes (though this signal differed by vaccine status) and significant 261 genetic structure. However, we found evidence of frequent reversion substitutions among viruses 262 classified as Sabin-like, suggesting that current definitions of cVDPVs may exclude circulating 263 viruses that have regained key virulence-associated mutations and which may pose a public 264 health risk.

265

266 VP1 informativeness

Polioviruses are among the fastest evolving RNA viruses and we observed that the rapid generation of genetic diversity in vaccinated children and their household and community contacts contains epidemiological information. Early evolution of OPV is largely clocklike, with variation in mutation rate across serotypes. The lack of a signal of clocklike evolution of OPV-2 and OPV-3 in vaccinated children likely reflects the shorter sampling period for vaccinated children; unvaccinated household and community contacts were infected later in the study by vaccine-derived viruses which had already passed through at least one host.

Our estimate of the OPV-1 VP1 substitution rate of 1.2×10^{-4} substitutions/site/day 274 275 (including all samples) was similar to previous estimates of OPV-1 evolution 0.83×10^{-4} substitutions/site/day²⁰ (estimated from three years of surveillance for acute flaccid paralysis) 276 277 and faster than the estimate of the molecular clock for wild poliovirus type 1 evolution of 0.28 x278 10^{-4} substitutions/site/day, estimated from a set of 31 viruses sampled over ten years¹⁰. The 279 differences in substitution rate may reflect the different sampling durations, as shorter sampling 280 durations often yield higher pathogen substitution rates estimates, likely because purifying 281 selection has not yet removed transient deleterious mutations are still present prior to the effect of purifying selection 21,22 . It is also likely that Sabin vaccine viruses evolve more rapidly than 282 283 wildtype viruses.

We observe moderate genetic structure in VP1 sequences, with increasing genetic divergence between samples from different communities compared to that sampled within the same community, household, or longitudinally within an individual. Yet VP1 divergence is not sufficient to make predictions about transmission linkage. Whole genome sequences and additional epidemiological information about timing of infection and contacts could improve inference of transmission networks.

290

291 Reversion to virulence

The rapid reversion to virulence of Sabin vaccines is well documented^{23–25}. While each serotype has key attenuating mutations in the IRES, additional mutations along the genome, including in the VP1 gene, stabilize the attenuated phenotype²⁶. In OPV-2, a predictable evolutionary route towards virulence includes gatekeeper mutations including an IRES mutation,

followed by a VP1 gene mutation, and a reversion in the 5' UTR, followed by a wave of
 recombination events^{27,28}.

298 We found a high frequency of attenuating substitutions in VP1, with substitutions 299 appearing early after vaccination. The higher frequency of OPV-2 and OPV-3 reversion 300 mutations we observed could reflect the greater observed genetic stability of OPV-1, which 301 differs from the virulent wild-type progenitor virus by 59 substitutions, compared to OPV-2 and OPV-3 which are more closely related to the virulent ancestor²⁹. Our group previously found that 302 303 97% of OPV-3 recipients shed viruses that had a site 472 reversion mutation within two weeks following vaccination^{30,31}. The instability of OPV-3 has epidemiological consequences: OPV-3 304 305 causes the majority of vaccine-associated paralytic poliomyelitis (VAPP), paralysis attributable 306 to the vaccine itself, followed by OPV-2 and then $OPV-1^3$.

However, previous studies have reported heterogeneity at the OPV-3 C2493U attenuating mutation in vaccine stocks³². We did not have access to vaccine stocks and therefore cannot determine if the near-fixation of an attenuating mutation we observe was due to heterogeneity in the vaccine or *de novo* evolution in vaccinated children and subsequent onwards transmission.

311

312 Identifying viruses of public health concern

Although the majority of OPV samples in our study collected were defined as Sabin-like viruses, rather than VDPVs, based on sequence divergence, many of the Sabin-like viruses had rapidly lost attenuating mutations at previously described positions. While VP1 sequence divergence may be useful in estimating duration of circulation or predicting transmission cluster, OPV circulating for short periods, that does not yet meet GPEI definitions for a cVDPV, can be virulent and can pose a public health risk in populations without prior immunity. For example, 319 Sabin-like OPV-2 viruses, which were 3 SNPs distant to the Sabin virus VP1 sequence, were 320 previously found to have caused a cluster of acute flaccid paralysis cases in an orphanage in Altai Region of Russia³³. All outbreak genomes shared 15 substitutions compared to the Sabin 321 322 virus, including the loss of attenuation mutations A481G and U2909C 323 The global increase of cVDPV2 outbreaks has increased dramatically since 2016, when Sabin 2 was removed from the trivalent poliovirus vaccine⁵. Our results are consistent with 324 325 previous work on the genetic instability of OPV and rapid reversion to virulence. Our finding 326 that current definitions of cVDPVs may exclude virulent Sabin-like viruses underscores the 327 urgency in heightened surveillance during and following vaccination campaigns. 328 329 **Funding Information** 330 This project was funded by the National Institutes of Health 5R21AI148810 to YM. KSW was

331 funded by a Thrasher Early Career Award and a Stanford Child Health Research Institute

332 postdoctoral fellowship.

333 Figure 1. The increasing global burden of vaccine-derived poliovirus. (a) Confirmed cases of

334 paralytic polio reported to the World Health Organization from 2000-2022. Color indicates source:

circulating vaccine derived poliovirus (cVDPV) and wild poliovirus cases. (b) Map of countries reporting
 cVDPV cases in from 2020-2022; fill indicates number of cVDPV cases identified. Data from the World

- Health Organization.
- 338



- cVDPV Cases - Wild poliovirus cases



340 Figure 2. Prospective study of OPV shedding among vaccinated children, household members, and

- **341 community members following a vaccination campaign.** (a) Map of Mexico with Veracruz State
- highlighted and Orizaba city, where the study took place, indicated with a red point. (b) We conducted a
- 343 prospective observational study of OPV viral shedding following a vaccination campaign. 155 children 344 were enrolled and vaccinated with trivalent OPV. Stool was collected from vaccinated children,
- 344 were enrolled and vaccinated with trivalent OPV. Stool was collected from vaccinated children, 345 unvaccinated household members, and community members in unvaccinated households. We extra
- unvaccinated household members, and community members in unvaccinated households. We extracted
 RNA from stool samples, tested samples with OPV serotype-specific RT-PCR, and Sanger sequenced
- 347 positive samples.





- 350 Figure 3. Limited overall genetic diversity in sampled OPV viral capsid protein 1 (VP1) gene
- **following vaccination campaigns.** For each OPV serotype and sampling site, haplotype networks of
- 352 OPV VP1 representing sampled genetic diversity. Nodes indicate identical haplotypes (VP1 consensus
- 353 sequences) and node size indicates the number of samples sharing a haplotype. Points on edges between 354 nodes indicate the SNP distance between haplotypes and node colors indicate individual's vaccination
- status. Labels indicate OPV serotype and study site. Site C, Capoluca, had 70% vaccination coverage of
- eligible children; site CG, Campo Grande: 30%; site T, Tuxpanguillo: 10%. One sample with a distant
- 357 haplotype (>14 SNPs distant to the Sabin vaccine) was removed from OPV-2 site C, to aid visualization.



359 Figure 4. Measurable evolution in the OPV VP1 gene following vaccination campaigns. Genetic 360 distance of the OPV VP1 gene to the Sabin vaccine strain versus time from vaccination for vaccinated 361 children (blue) and not vaccinated study participants, including household contacts and unvaccinated 362 community members (red), for each OPV serotype (a-c). Black lines and grey shading of a linear model 363 for distance to the Sabin strain. Days following vaccination is measured as days from first vaccination (for vaccinated children), day from first household vaccination (for non-vaccinated household members), 364 365 and days from first community vaccination (for non-vaccinated community members). Red dashed lines 366 indicate the genetic distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for 367 serotypes 1 and 3 and 6 SNPs distant for serotype 2.





370 Figure 5. Moderate genetic structure of OPV VP1 gene from samples shed two months following

vaccination campaigns. The proportion of pairs of OPV VP1 sequences within a given, binned pairwise
 genetic distance for samples collected longitudinally from the same individual, from the same household,
 the same community, or outside the community. Facets indicate OPV serotype.



376 Figure 6. Loss of OPV attenuating mutations following vaccination. For each serotype, points indicate 377 the revertant proportion, the proportion of samples with a mutation at a key attenuating position in OPV 378 in the weeks following vaccination. Bars indicate the total number of sequences available for that 379 sampling week. Each serotype has unique attenuating sites.



383 Supplementary Figures

384

385 Figure S1. Measurable evolution in the OPV VP1 gene following vaccination campaigns when

excluding attenuating mutations. Genetic distance of the OPV VP1 gene to the Sabin vaccine strain

versus time from vaccination for vaccinated children (blue) and not vaccinated study participants (red),

388 for each OPV serotype (a-c). Black lines and grey shading of a linear model for distance to the Sabin

- 389 strain. Days following vaccination is measured as days from first vaccination (for vaccinated children),
- day from first household vaccination (for non-vaccinated household members), and days from first
 community vaccination (for non-vaccinated community members). Red dashed lines indicate the genetic
- distance threshold for a cVDPV: 10 SNPs distant from the Sabin vaccine for serotypes 1 and 3 and 6
- 393 SNPs distant for serotype 2.



- Khan, F. et al. Progress Toward Polio Eradication Worldwide, January 2016–March 2018.
 Morb. Mortal. Wkly. Rep. 67, 524 (2018).
- Jorba, J. et al. Update on Vaccine-Derived Poliovirus Outbreaks Worldwide, January 2018– June 2019. *Morb. Mortal. Wkly. Rep.* 68, 1024 (2019).
- 399 3. Platt, L. R., Estivariz, C. F. & Sutter, R. W. Vaccine-Associated Paralytic Poliomyelitis: A Review
 400 of the Epidemiology and Estimation of the Global Burden. *J. Infect. Dis.* 210, S380–S389 (2014).
- 401
 4. Chumakov, K. M., Brechot, C., Gallo, R. C. & Plotkin, S. Choosing the Right Path toward Polio
 402
 403
 404
 405
 405
 405
 406
 407
 407
 408
 408
 408
 409
 409
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400
 400</li
- 403 5. Macklin, G. R. et al. Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016
 404 and 2020. *Vaccine* (2022) doi:10.1016/j.vaccine.2022.08.008.
- 405 6. Global Polio Eradication Initiative. *Classification and reporting of vaccine-derived polioviruses*406 (*VDPV*) *GPEI guidelines*. http://polioeradication.org/wp-content/uploads/2016/09/Reporting407 and-Classification-of-VDPVs_Aug2016_EN.pdf (2016).
- Jorgensen, D., Pons-Salort, M., Shaw, A. G. & Grassly, N. C. The role of genetic sequencing and analysis in the polio eradication programme. *Virus Evol.* 6, (2020).
- 410 8. Jorba, J. Phylogenetic analysis of poliovirus sequences. *Methods Mol. Biol.* **1387**, 227–237 (2016).
- 411 9. Burns, C. C. et al. Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses
 412 during a Large Outbreak in Northern Nigeria. J. Virol. 87, 4907–4922 (2013).
- 413 10. Jorba, J., Campagnoli, R., De, L. & Kew, O. Calibration of Multiple Poliovirus Molecular Clocks
 414 Covering an Extended Evolutionary Range. J. Virol. 82, 4429–4440 (2008).
- 415 11. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong
 416 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* 29, 32-43.e4 (2021).
 417 12 Starm A at al. The Evolutionary Bathway to Virulance of an BNA Virus. *Cell* 160, 35 46 a10.
- 417 12. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* 169, 35-46.e19
 418 (2017).
- 419 13. Sarnquist, C. et al. Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After
 420 Cessation of Routine Oral Poliovirus Vaccine Immunization. *Clin. Infect. Dis.* 67, S115–S120
 421 (2018).
- 422 14. Troy, S. B. et al. Use of a novel real-time PCR assay to detect oral polio vaccine shedding and
 423 reversion in stool and sewage samples after a mexican national immunization day. *J. Clin.*424 *Microbiol.* 49, 1777–83 (2011).
- 425 15. Kilpatrick, D. R. et al. Poliovirus serotype-specific VP1 sequencing primers. J. Virol. Methods
 426 174, 128–130 (2011).
- 16. Nakamura, T., Yamada, K. D., Tomii, K. & Katoh, K. Parallelization of MAFFT for large-scale
 multiple sequence alignments. *Bioinformatics* 34, 2490–2492 (2018).
- 429 17. Paradis, E. & Schliep, K. Ape 5.0: An environment for modern phylogenetics and evolutionary
 430 analyses in R. *Bioinformatics* 35, 526–528 (2019).
- 431 18. Paradis, E. pegas: an {R} package for population genetics with an integrated--modular approach.
 432 *Bioinformatics* 26, 419–420 (2010).
- 433 19. Wahid, R. et al. Genetic and phenotypic stability of poliovirus shed from infants who received
 434 novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
 435 *The Lancet Microbe* 3, e912–e921 (2022).
- 436 20. Famulare, M. et al. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria. J. Virol. 90, 317–331 (2016).
- 438 21. Duchêne, S., Holmes, E. C. & Ho, S. Y. W. Analyses of evolutionary dynamics in viruses are
 439 hindered by a time-dependent bias in rate estimates. *Proc. R. Soc. B Biol. Sci.* 281, (2014).
- 440 22. Holmes, E. C. Molecular Clocks and the Puzzle of RNA Virus Origins. J. Virol. 77, 3893 (2003).
- 441 23. Kew, O. M., Sutter, R. W., de Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. VACCINE442 DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO
 443 ERADICATION. *Annu. Rev. Microbiol.* 59, 587–635 (2005).
- 444 24. Duintjer Tebbens, R. J. et al. Oral poliovirus vaccine evolution and insights relevant to modeling 445 the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal.* **33**, 680–702 (2013).

- Burns, C. C., Diop, O. M., Sutter, R. W. & Kew, O. M. Vaccine-derived polioviruses. *J. Infect. Dis.* 210, S283–S293 (2014).
 Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine-Derived Polioviruses and the Endgame Strategy for Global Polio Eradication *. (2005) doi:10.1146/annurev.micro.58.030603.123625.
 Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* 169, 35-46.e19
- 451 27. Stern, A. et al. The Evolutionary Pathway to Virulence of an RNA Virus. *Cell* 169, 35-46.e19
 452 (2017).
- 453 28. Valesano, A. L. et al. The Early Evolution of Oral Poliovirus Vaccine Is Shaped by Strong
 454 Positive Selection and Tight Transmission Bottlenecks. *Cell Host Microbe* 29, 32-43.e4 (2021).
- 455 29. Kew, O. M., Sutter, R. W., De Gourville, E. M., Dowdle, W. R. & Pallansch, M. A. Vaccine456 derived polioviruses and the endgame strategy for global polio eradication. *Annual Review of*457 *Microbiology* vol. 59 587–635 (2005).
- 458 30. Gnanashanmugam, D. et al. Shedding and Reversion of Oral Polio Vaccine Type 3 in Mexican
 459 Vaccinees: Comparison of Mutant Analysis by PCR and Enzyme Cleavage to a Real-Time PCR
 460 Assay. J. Clin. Microbiol. 45, 2419 (2007).
- 461 31. Martinez, C. V. et al. Shedding of Sabin poliovirus type 3 containing the nucleotide 472 uracil-to462 cytosine point mutation after administration of oral poliovirus vaccine. *J. Infect. Dis.* 190, 409–
 463 416 (2004).
- 464 32. Neverov, A. & Chumakov, K. Massively parallel sequencing for monitoring genetic consistency
 465 and quality control of live viral vaccines. *Proc. Natl. Acad. Sci. U. S. A.* 107, 20063–20068 (2010).
- 466 33. Korotkova, E. A. et al. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly
 467 Diverged Sabin 2 Vaccine Poliovirus. J. Virol. 90, 5978 (2016).
- 468